Diagnosis and Treatment > Signs and Symptoms > Abdominal cramp
You are looking at 1 - 2 of 2 items
Search for other papers by Anna Tortora in
Google Scholar
PubMed
Search for other papers by Domenico La Sala in
Google Scholar
PubMed
Search for other papers by Mario Vitale in
Google Scholar
PubMed
Summary
Reduced intestinal absorption of levothyroxine (LT4) is the most common cause of failure to achieve an adequate therapeutic target in hypothyroid patients under replacement therapy. We present the case of a 63-year-old woman with autoimmune hypothyroidism previously well-replaced with tablet LT4 who became unexpectedly no more euthyroid. At presentation, the patient reported the onset of acute gastrointestinal symptoms characterized by nausea, loss of appetite, flatulence, abdominal cramps and diarrhea, associated with increase of thyrotropin levels (TSH: 11 mIU/mL). Suspecting a malabsorption disease, a thyroxine solid-to-liquid formulation switch, at the same daily dose, was adopted to reach an optimal therapeutic target despite the gastrointestinal symptoms persistence. Oral LT4 solution normalized thyroid hormones. Further investigations diagnosed giardiasis, and antibiotic therapy was prescribed. This case report is compatible with a malabsorption syndrome caused by an intestinal parasite (Giardia lamblia). The reduced absorption of levothyroxine was resolved by LT4 oral solution.
Learning points:
-
The failure to adequately control hypothyroidism with oral levothyroxine is a common clinical problem.
-
Before increasing levothyroxine dose in a patient with hypothyroidism previously well-controlled with LT4 tablets but no more in appropriate therapeutic target, we suggest to investigate non adhesion to LT4 therapy, drug or food interference with levothyroxine absorption, intestinal infection, inflammatory intestinal disease, celiac disease, lactose intolerance, short bowel syndrome after intestinal or bariatric surgery, hepatic cirrhosis and congestive heart failure.
-
LT4 oral solution has a better absorptive profile than the tablet. In hypothyroid patients affected by malabsorption syndrome, switch of replacement therapy from tablet to liquid LT4 should be tested before increasing the dose of LT4.
Search for other papers by Marco Russo in
Google Scholar
PubMed
Search for other papers by Ilenia Marturano in
Google Scholar
PubMed
Search for other papers by Romilda Masucci in
Google Scholar
PubMed
Search for other papers by Melania Caruso in
Google Scholar
PubMed
Search for other papers by Maria Concetta Fornito in
Google Scholar
PubMed
Search for other papers by Dario Tumino in
Google Scholar
PubMed
Search for other papers by Martina Tavarelli in
Google Scholar
PubMed
Search for other papers by Sebastiano Squatrito in
Google Scholar
PubMed
Search for other papers by Gabriella Pellegriti in
Google Scholar
PubMed
Summary
Struma ovarii is a rare ovarian teratoma characterized by the presence of thyroid tissue as the major component. Malignant transformation of the thyroidal component (malignant struma ovarii) has been reported in approximately 5% of struma ovarii. The management and follow-up of this unusual disease remain controversial. We report the case of a woman with a history of autoimmune thyroiditis and a previous resection of a benign struma ovarii that underwent hystero-annexiectomy for malignant struma ovarii with multiple papillary thyroid cancer foci and peritoneal involvement. Total thyroidectomy and subsequent radioiodine treatment lead to complete disease remission after 104 months of follow-up. The diagnosis and natural progression of malignant struma ovarii are difficult to discern, and relapses can occur several years after diagnosis. A multidisciplinary approach is mandatory; after surgical excision of malignant struma, thyroidectomy in combination with 131I therapy should be considered after risk stratification in accordance with a standard approach in differentiated thyroid cancer patients.
Learning points
-
Malignant struma ovarii is a rare disease; diagnosis is difficult and management is not well defined.
-
Predominant sites of metastasis are adjacent pelvic structures.
-
Thyroidectomy and 131I therapy should be considered after risk stratification in accordance with standard approaches in DTC patients.